A
Aronora develops novel therapeutics focused on cardio-hematology to address unmet needs in thrombosis and thromboembolic events. The company's pipeline includes first-in-class and best-in-class medicines targeting biological drivers such as Protein C, Factor XI, Factor XII, and Thrombopoietin. These programs aim to provide effective treatments that improve patient quality of life beyond current standards of care.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Aronora develops novel therapeutics focused on cardio-hematology to address unmet needs in thrombosis and thromboembolic events. The company's pipeline includes first-in-class and best-in-class medicines targeting biological drivers such as Protein C, Factor XI, Factor XII, and Thrombopoietin. These programs aim to provide effective treatments that improve patient quality of life beyond current standards of care.